Yarbrough Capital’s Moderna MRNA Stock Holding History

Yarbrough Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$18K	–	219
2022 Q4	$18K	Buy	+100	New	+$16.4K	﹤0.01%	204
2022 Q1	–	Sell	-3,000	Closed	-$762K	–	222
2021 Q4	$762K	Buy	+3,000	New	+$877K	0.04%	122

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Yarbrough Capital's MRNA Position: Q1 2023 in Review

Yarbrough Capital sold out of Moderna (MRNA) in Q1 2023, closing a stake of 100 shares — an estimated $18K sold.

Yarbrough Capital first reported a position in MRNA in Q4 2021 and held it in 2 quarters. The position peaked at $762K in Q4 2021. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Yarbrough Capital reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Yarbrough Capital sold 100 Moderna shares in Q1 2023, an estimated $18K.
Yarbrough Capital first reported a position in Moderna in Q4 2021 and held it in 2 quarters.
Yarbrough Capital's Moderna position peaked at $762K in Q4 2021.
1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Yarbrough Capital's 13F filing for Q1 2023, filed 13 Apr 2023.